Expert opinion on the creating and operating of the regional Pulmonary Embolism Response Teams (PERT). Polish PERT Initiative.


Journal

Cardiology journal
ISSN: 1898-018X
Titre abrégé: Cardiol J
Pays: Poland
ID NLM: 101392712

Informations de publication

Date de publication:
2019
Historique:
received: 30 11 2019
accepted: 14 01 2020
revised: 11 01 2020
entrez: 24 1 2020
pubmed: 24 1 2020
medline: 4 8 2020
Statut: ppublish

Résumé

Pulmonary Embolism Response Team (PERT) is a multidisciplinary team established to stratify risk and choose optimal treatment in patients with acute pulmonary embolism (PE). Established for the first time at Massachusetts General Hospital in 2013, PERT is based on a concept combining a Rapid Response Team and a Heart Team. The growing role of PERTs in making individual therapeutic decisions is identified, especially in hemodynamically unstable patients with contraindications to thrombolysis or with co-morbidities, as well as in patients with intermediate-high risk in whom a therapeutic decision may be difficult. The purpose of this document is to define the standards of PERT under Polish conditions, based on the experience of teams already operating in Poland, which formed an agreement called the Polish PERT Initiative. The goals of Polish PERT Initiative are: improving the treatment of patients with PE at local, regional and national levels, gathering, assessing and sharing data on the effectiveness of PE treatment (including various types of catheter-directed therapy), education on optimal treatment of PE, creating expert documents and supporting scientific research, as well as cooperation with other communities and scientific societies.

Identifiants

pubmed: 31970735
pii: VM/OJS/J/66693
doi: 10.5603/CJ.2019.0127
pmc: PMC8083021
doi:

Types de publication

Journal Article Practice Guideline

Langues

eng

Sous-ensembles de citation

IM

Pagination

623-632

Références

Lancet. 1993 Feb 27;341(8844):507-11
pubmed: 8094768
Pulm Circ. 2019 Jan 11;:2045894018824563
pubmed: 30632901
Int J Cardiol. 2016 Dec 15;225:128-139
pubmed: 27718446
Int J Cardiol. 2013 Oct 9;168(4):3543-9
pubmed: 23711442
Circulation. 2000 Jun 20;101(24):2817-22
pubmed: 10859287
Chest. 2016 Dec;150(6):1414-1417
pubmed: 27938758
Am J Med. 2018 Apr;131(4):442.e9-442.e12
pubmed: 29132839
Am J Med. 2012 May;125(5):465-70
pubmed: 22325236
Hosp Pract (1995). 2014 Feb;42(1):31-7
pubmed: 24566594
Chest. 2010 Jan;137(1):164-70
pubmed: 19592472
Med Care. 2018 Mar;56(3):260-265
pubmed: 29356721
Kardiol Pol. 2018;76(5):931
pubmed: 29756201
Postepy Kardiol Interwencyjnej. 2019;15(4):497-498
pubmed: 31933670
Kardiol Pol. 2017;75(11):1161-1170
pubmed: 28715074
Pol Arch Intern Med. 2017 Aug 9;127(7-8):567-568
pubmed: 28817549
N Engl J Med. 2014 Apr 10;370(15):1402-11
pubmed: 24716681
EuroIntervention. 2018 Feb 20;13(14):1721-1727
pubmed: 29175770
Transplant Proc. 2018 Sep;50(7):1957-1961
pubmed: 30177087
Kardiol Pol. 2018;76(9):1381
pubmed: 30211948
JACC Cardiovasc Interv. 2018 Jul 23;11(14):1401-1410
pubmed: 30025734
Chest. 2016 Aug;150(2):384-93
pubmed: 27006156
N Engl J Med. 1998 Feb 12;338(7):409-15
pubmed: 9459643
Circulation. 2016 Jan 5;133(1):98-103
pubmed: 26719388
JAMA. 2014 Jun 18;311(23):2414-21
pubmed: 24938564
Kardiol Pol. 2015;73(1):63-8
pubmed: 25625343
Kardiol Pol. 2019;77(2):228-231
pubmed: 30566224
Chest. 2006 Apr;129(4):1043-50
pubmed: 16608956
J Thromb Thrombolysis. 2019 Jan;47(1):31-40
pubmed: 30242551
Chest. 2013 Nov;144(5):1738-1739
pubmed: 24189880
Pol Arch Intern Med. 2018 Jun 30;128(6):394-395
pubmed: 29806658
Eur Respir J. 2014 Sep;44(3):694-703
pubmed: 24696111
Circulation. 2014 Jan 28;129(4):479-86
pubmed: 24226805
Eur Heart J. 2019 Nov 1;40(42):3453-3455
pubmed: 31697840
Thromb Haemost. 2007 Oct;98(4):756-64
pubmed: 17938798
Wideochir Inne Tech Maloinwazyjne. 2018 Jun;13(2):233-242
pubmed: 30002757
Lancet. 2012 May 12;379(9828):1835-46
pubmed: 22494827
Circulation. 2005 Jul 19;112(3):416-22
pubmed: 16009794
Circulation. 2011 Nov 8;124(19):2139-44
pubmed: 22064957

Auteurs

Aleksander Araszkiewicz (A)

1st Department of Cardiology, University of Medical Sciences,Poznan, Poland, Dluga 1/2, 61-848 Poznan, Poland. aaraszkiewicz@interia.pl.

Marcin Kurzyna (M)

Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology European Health Centre Otwock, Medical Centre for Postgraduate Education, Otwock, Poland.

Grzegorz Kopeć (G)

Department of Cardiac and Vascular Diseases, Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland.

Marek Roik (M)

Department of Internal Medicine and Cardiology, Medical University of Warsaw, Poland, Poland.

Szymon Darocha (S)

Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology European Health Centre Otwock, Medical Centre for Postgraduate Education, Otwock, Poland.

Arkadiusz Pietrasik (A)

Department and Faculty of Cardiology, Medical University of Warsaw, Warsaw, Poland.

Mateusz Puślecki (M)

Department of Medical Rescue and Department of Cardiac Surgery and Transplantology, Poznan University of Medical Sciences, Poznan, Poland.

Andrzej Biederman (A)

Department of Cardiac Surgery, Medicover Hospital, Warsaw, Poland.

Roman Przybylski (R)

Department of Cardiovascular Surgery and Transplantology, John Paul II Hospital, Krakow, Poland.

Jakub Stępniewski (J)

Department of Cardiac and Vascular Diseases, Jagiellonian University Medical College, John Paul II Hospital, Krakow, Poland.

Michał Furdal (M)

Department of Cardiology, Provincial Specialist Hospital, Wroclaw, Poland.

Tatiana Mularek-Kubzdela (T)

1st Department of Cardiology, University of Medical Sciences,Poznan, Poland, Dluga 1/2, 61-848 Poznan, Poland.

Piotr Pruszczyk (P)

Department of Internal Medicine and Cardiology, Medical University of Warsaw, Poland, Poland.

Adam Torbicki (A)

Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology European Health Centre Otwock, Medical Centre for Postgraduate Education, Otwock, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH